Control of long-lived HIV cellular reservoirs in memory CD4+ T cells by BACH2

Active Project Grant Awarded Last action

Award ID
R56AI186666
Recipient
Awarding agency
Obligated
$1,498,650

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 74% complete
Originally
Place of performance
Missouri, USA

Award details come from USAspending.gov.

Description

Abstract
Despite effective antiretroviral therapy (art), HIV-1 mainly persists in a small pool of latently infected, resting memory CD4+ T cells in people living with HIV-1 (PLWH). Virus eradication with art alone will not be possible. The stability of the viral reservoir is a consequence of infection of cells that either have expanded or are destined to expand in response to cognate antigens or cytokines. CCR5 and CXCR4 are two CO-receptors for HIV-1 entry. CCR5-tropic virus is critical for the establishment of infection and dominates the pool of viruses in blood and tissues early after infection. In PLWH, latent HIV-1 is predominantly CCR5-tropic, which is a reflection of selective transmission and dominant replication of CCR5-tropic virus before art initiation. CCR5 is expressed predominantly by terminally differentiated CD4+ T cells which lose proliferation capacity and are prone to cell death. To seed the latent reservoir, CCR5-expressing CD4+ T cells are infected, carry integrated and transcriptionally silent HIV-1 provirus, and differentiate into long- lived memory cells. To maintain the latent reservoir, cells carry integrated HIV-1 proviruses proliferate despite potential viral cytopathic effects or immune clearance. Therefore, studies on the mechanisms suppressing terminal differentiation of CCR5+CD4+ T cells are significant. In this study, we plan to address the following three questions. 1) how does BACH2 inhibit terminal differentiation of CCR5+CD4+ T cells and how does IT impact viral reservoir seeding in humanized mice? 2) can BACH2-mediated differentiation of CCR5+CD4+ T cells results in long-lived memory cells with proliferation capacity? 3) can we target BACH2 or its downstream molecules to prevent HIV reservoir seeding? Understanding this process can help US develop strategies to block seeding or expansion of the stable viral latent reservoirs in vivo.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $499,550
Amendment $499,550
Original award $499,550

Quick answers

Who received award R56AI186666?

R56AI186666 was awarded to The Washington University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 15, 2025.

How much is award R56AI186666 worth?

$1,498,650 has been obligated on R56AI186666.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award